As author, I had access to sufficient data to meaningfully contribute to a publication: 26.5% (n=110) agree, 27.2% (n=113) neither agree nor disagree, 10.4% (n=43) disagree, and 1.4% (n=6) strongly disagree.

I have been adequately informed on the respective requirements of the target journals: 52.0% (n=216) agree, 27.7% (n=115) neither agree nor disagree, 10.4% (n=43) disagree, and 0.7% (n=3) strongly disagree.

Overall, I think the communication channel established by GSK Vaccines' publication team is clear, proactive and streamlined: 54.7% (n=227) agree, 27.7% (n=115) neither agree nor disagree, 10.4% (n=43) disagree, and 1.2% (n=5) strongly disagree.

GSK Vaccines' publication process development adequately follows the international good publication practices and reporting guidelines: 59.5% (n=247) agree, 29.4% (n=122) neither agree nor disagree, 1.2% (n=5) disagree, and 0.7% (n=3) strongly disagree.